Home › Companies › MBRX

Moleculin Biotech

Market cap $7.3M 1.1M shares (10-Q, Nov 6, 2026) × $6.83 close Nov 17, 2026

Most recent annual filing: 2026-03-18

Catalyst timeline

6 trackedQuarter catalyst calendar →
  1. WP1066 readout2H 2026WP1066 readout, 2H 2026, notable
  2. Annamycin pancreatic Ph1 start2H 2026Annamycin pancreatic Ph1 start, 2H 2026, routine
  3. Annamycin filing4Q 2026Annamycin filing, 4Q 2026, notable
  4. Annamycin topline1Q 2027Annamycin topline, 1Q 2027, thesis-defining
  5. Annamycin Ph3 start1H 2027Annamycin Ph3 start, 1H 2027, routine
  6. Annamycin financing~Jan 30, 2027Annamycin financing, ~Jan 30, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Discontinued (3)

Capital (as filed)

Cash
$7.3M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$9.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$7.3M cash, runway first quarter of 2027 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on Moleculin Biotech, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Moleculin Biotech (MBRX) - Scientific Deep Dive for Annamycin and Pipeline Products The cardiolipin-avoidance chemistry and 90-patient cardiac dataset clear the scientific bar, but a delisting determination with no cure period, a required pre-data financing, and a 37.1M-share ratchet mean the equity may not survive to collect on the December–February readout.
  2. Watch UPDATE: Moleculin Biotech (MBRX) - The Delisting Letter Arrives On Schedule The delisting letter arrived on schedule but the feared immediate suspension did not occur; the appeal keeps MBRX trading, but the pre-data financing requirement, ratchet, and drifting blinded CR rate are unchanged.
  3. Avoid UPDATE: Moleculin Biotech (MBRX) - The Ratchet Fires A $0.48M ATM sale below $0.75 triggered the full-ratchet clause, resetting 37.1M Series I warrants from $0.75 to $0.51 — the exact downgrade condition the author had pre-specified — making a good December readout a smaller payoff for common holders.
  4. Avoid UPDATE: Moleculin Biotech (MBRX) - Enrollment Closes, Expectations Come Down The Q1 2027 readout now lands on top of the cash-exhaustion quarter, management is pre-framing weaker absolute response rates due to a harder venetoclax-failure patient mix, and none of the conditions for returning to WATCH LIST have been met.
  5. Avoid UPDATE: Moleculin Biotech (MBRX) - The Second Reverse Split A second reverse split (1-for-20) cures the bid-price problem but leaves 500M authorized shares over ~1.05M outstanding, the BTD request slipped to Q4, and none of the conditions for returning to WATCH LIST have been met ahead of the Q1 2027 binary on top of the cash cliff.
  6. Avoid UPDATE: Moleculin Biotech (MBRX) - The Panel Says Yes, The Ratchet Fires Again The Nasdaq Panel granted a listing exception (one of two required conditions for an upgrade) but the ratchet fired again on a ~$0.14M ATM sale, Q3 burn accelerated to ~$9M, and the company now needs ~$7M more just to reach Q2 2027, so the warrant overhang worsens while common holders' share of any upside shrinks further.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (66)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)